본문 바로가기

New onset diabetes mellitus and cardiovascular events in Korean patients with acute myocardial infarction receiving high-intensity statins

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q3Scopus Q2
피인용
Web of Science 3Scopus 4
FWCI (Scopus)
0.32
JCR IF
JCR 2020 2.483
ISSN
2050-6511

저자

  1. Choi, Jah Yeon제1저자고려대학교, Cardiovasc Ctr, Guro Hosp, KO
  2. Choi, Cheol Ung교신저자고려대학교, Cardiovasc Ctr, Guro Hosp, KO
  3. Choi, Byoung Geol고려대학교, Cardiovasc Ctr, Guro Hosp, KO
  4. Park, Yoonjee고려대학교, Cardiovasc Ctr, Guro Hosp, KO
  5. Kang, Dong Oh고려대학교, Cardiovasc Ctr, Guro Hosp, KO
  6. Jang, Won Young가톨릭대학교, Cardiovasc Ctr, St Vincent Hosp, KO
  7. Kim, Woohyeun고려대학교, Cardiovasc Ctr, Guro Hosp, KO
  8. Na, Jin Oh고려대학교, Cardiovasc Ctr, Guro Hosp, KO
  9. Kim, Jin Won고려대학교, Cardiovasc Ctr, Guro Hosp, KO
  10. Kim, Eung Ju고려대학교, Cardiovasc Ctr, Guro Hosp, KO
  11. Rha, Seung-Woon고려대학교, Cardiovasc Ctr, Guro Hosp, KO
  12. Park, Chang Gyu고려대학교, Cardiovasc Ctr, Guro Hosp, KO
  13. Seo, Hong Seog고려대학교, Cardiovasc Ctr, Guro Hosp, KO
  14. Jeong, Myung Ho전남대학교, KO
  15. Chae, Sung-Chull경북대학교, Kyungbook Natl Univ Hosp, Sch Med, KO
  16. Seong, In-Whan충남대학교, KO
  17. Yoon, Chang-Hwan서울대학교, Bundang Hosp, KO
  18. 차광수부산대학교, 의과대학, 의학과, KO
  19. Oh, Seok Kyu원광대학교, Sch Med, KO

초록

BackgroundHigh-intensity statin therapy is typically used in patients with acute myocardial infarction (AMI) for secondary prevention. However, there have been consistent concerns regarding its association with diabetes mellitus. We investigated the effect of high-intensity atorvastatin and rosuvastatin on new-onset diabetes mellitus (NODM) and cardiovascular outcomes over a 3-year follow-up period.MethodsData from the Korea Acute Myocardial Infarction Registry were collected from November 2011 to October 2015, and 13,104 patients with AMI were enrolled from major cardiovascular centers. Among them, 2221 patients without diabetes who had been administered with high-intensity atorvastatin (40-80mg) and rosuvastatin (20mg) were investigated. The atorvastatin and rosuvastatin groups were evaluated for the incidence of NODM and major adverse cardiac events (MACE) including death, myocardial infarction, and revascularization cases in the following 3years.ResultsBaseline characteristics were comparable between the two groups. Event-free survival rate of NODM was not significantly different between the atorvastatin and rosuvastatin groups (92.5% vs. 90.8%, respectively; Log-rank P-value=0.550). The event-free survival rate of MACE was also not significantly different between atorvastatin and rosuvastatin groups (89.0% vs. 89.6%, respectively; Log rank P-value=0.662). Multivariate Cox analysis revealed that statin type was not a prognostic factor in the development of NODM and MACE.ConclusionsAdministering high-intensity atorvastatin and rosuvastatin in patients with AMI produced comparable effects on NODM and clinical outcomes, suggesting their clinical equivalence in secondary prevention.

키워드

Acute myocardial infarctionNew-onset diabetes mellitusCardiovascular outcomeAtorvastatinRosuvastatinGENETIC-VARIANTSRISKTHERAPYATORVASTATINPREVENTIONDISEASEPCSK9

식별자

Scopus EID
2-s2.0-85101000757
WoS UID
000617208600002